Medical Cannabis and Behavior

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age35-65
SponsorUniversity of Minnesota

About this trial

This study will assess cognition, neural function, and drug exposure in chronic pain patients who have been prescribed medical cannabis and will differentiate outcomes based on use of specific CBD-dominant versus THC-dominant treatment products. This longitudinal study will recruit medical cannabis users from local dispensaries. Each participant will complete a baseline assessment prior to the start of medical cannabis use, monthly phone calls to assess treatment adherence, and a four-month follow- up assessment. The aims of this project are: Aim 1. To assess impacts of medical cannabis compounds on executive functions, learning and memory in adults to determine whether cognitive impairments are evident after the onset of cannabis use; Aim 2. To assess the impacts of medical cannabis compounds on white matter microstructure, functional brain activity and functional connectivity; Aim 3. To differentiate change over four months in these outcomes as a function of (a) age and (b) pre-to-post-treatment changes in blood levels of cannabinoid compounds.

Eligibility criteria

Qualifiers

Medical cannabis users (n=120) will be required to

Be ages 35-65;

Be qualified for a medical cannabis prescription based only on a diagnosis of chronic pain; note that individuals can, in theory, utilize medical cannabis for more than one qualifying condition. People with orthopedic pain will be prioritized.

Have normal or corrected-to-normal vision and hearing;

Disqualifiers

Cannot have a degenerative neurological condition or a neurological condition that impacts brain function (e.g., epilepsy);

No contraindications to MRI scanning;

No lifetime history of severe DSM-V psychopathology (psychotic disorders, bipolar disorder); if currently treated mood for anxiety disorders, must be stable;

No current pregnancy or pregnancy within the prior 3 months; cannot be lactating;

Trial design

Treatments tested in this trial

  • Cognitive testing
  • Task-based fMRI measure of inhibitory control
  • Task-based fMRI measure of face-name learning

Treatment groups

180 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Minnesota

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator